SynthesisScientific reports2017
Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy.
Synthesis in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Presentation and clinical course of pediatric-onset versus adult-onset Takayasu arteritis-a systematic review and meta-analysis.Clinical rheumatology · 2022Pooled it
- European Headache Federation recommendations for neurologists managing giant cell arteritis.The journal of headache and pain · 2020Pooled it
- Cross-phenotype analysis of Immunochip data identifiesAnnals of the rheumatic diseases · 2018Pooled it
- Inflammatory Aortopathies in Rheumatic Diseases: A State-of-the-Art Review.Diagnostics (Basel, Switzerland) · 2026Review
- Large vessel vasculitis reframed: integrating conceptual shifts and evidence into practice for Takayasu arteritis and giant cell arteritis.Journal of rheumatic diseases · 2026Review
- Advances in the pathophysiology, diagnosis and treatment of Takayasu arteritis.Nature reviews. Rheumatology · 2025Review
- Uncovering the New Biology of Giant Cell Arteritis to Guide Therapeutic Strategies.Journal of clinical medicine · 2025Review
- Proteomic Profiling of the Large-Vessel Vasculitis Spectrum Identifying Shared Signatures of Innate Immune Activation and Stromal Remodeling.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Estimating overdiagnosis in giant cell arteritis diagnostic pathways using genetic data: genetic association study.Rheumatology (Oxford, England) · 2024Article
- Frequency and the effects of spondyloarthritis-spectrum disorders on the clinical course and management of Takayasu arteritis: an observational retrospective study.Clinical rheumatology · 2024Observational
- Review
- Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing.Annals of the rheumatic diseases · 2023Article
- Design and Protocol for Beijing Hospital Takayasu Arteritis (BeTA) Biobank.Journal of clinical medicine · 2023Article
- Large-Vessel Giant Cell Arteritis following COVID-19-What Can HLA Typing Reveal?Diagnostics (Basel, Switzerland) · 2023Article
- Distinct gene signatures of monocytes and B cells in patients with giant cell arteritis: a longitudinal transcriptome analysis.Arthritis research & therapy · 2023Article
- Identification of a shared genetic risk locus for Kawasaki disease and immunoglobulin A vasculitis by a cross-phenotype meta-analysis.Rheumatology (Oxford, England) · 2022Article
- Large-vessel vasculitis.Nature reviews. Disease primers · 2022Review
- Pathogenesis of giant cell arteritis with focus on cellular populations.Frontiers in medicine · 2022Review
- Advances in Takayasu arteritis: An Asia Pacific perspective.Frontiers in medicine · 2022Review
- The Immunopathology of Giant Cell Arteritis Across Disease Spectra.Frontiers in immunology · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
19 authors.
Funding
Abstract
Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are major forms of large-vessel vasculitis (LVV) that share clinical features. To evaluate their genetic similarities, we analysed Immunochip genotyping data from 1,434 LVV patients and 3,814 unaffected controls. Genetic pleiotropy was also estimated. The HLA region harboured the main disease-specific associations. GCA was mostly associated with class II genes (HLA-DRB1/HLA-DQA1) whereas TAK was mostly associated with class I genes (HLA-B/MICA). Both the statistical significance and effect size of the HLA signals were considerably reduced in the cross-disease meta-analysis in comparison with the analysis of GCA and TAK separately. Consequently, no significant genetic correlation between these two diseases was observed when HLA variants were tested. Outside the HLA region, only one polymorphism located nearby the IL12B gene surpassed the study-wide significance threshold in the meta-analysis of the discovery datasets (rs755374, P = 7.54E-07; OR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.